Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase I clinical study for its small interfering RNA (siRNA) drug candidate, STP707, which has shown good safety and preliminary signs of activity in pancreatic cancer.
The dose-escalation study was conducted across 11 cancer clinics in the U.S., enrolling 50 patients with various cancer types, including pancreatic, colorectal, liver, melanoma, and others. Among them, 11 patients with pancreatic cancer (five men and six women with an average age of 64 years), who had previously been treated with up to three lines of therapy including gemcitabine, paclitaxel, and Folfirinox, achieved a stable condition (SD) after an average of 92 days following STP707 treatment. Notably, no treatment-related adverse events (TRAEs) were reported.
STP707 is designed as a dual siRNA oligonucleotide that targets TGF-β1 and COX-2 mRNA. It is combined with a histidine-lysine copolypeptide (HKP+H) carrier to create a nanoparticle formulation. Leveraging dual-targeted inhibitory properties and Sirnaomics’ proprietary PNP delivery technology, STP707 is designed to enhance the targeted delivery of drugs to both solid and metastatic tumors via systemic administration. The drug candidate works by inhibiting the expression of TGF-β1 and COX-2 simultaneously.- Flcube.com
